amg 592
Recombinant proteinexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 19, 2015 (NCT05873907)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05885451 | Phase 1 | Jan 29, 2019 | Amgen |
| NCT03410056 | Phase 1/Phase 2 (Phase 2) | May 22, 2018 | Amgen |
| NCT03422627 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2018 | Amgen |
| NCT03451422 | Phase 1/Phase 2 (Phase 2) | Apr 10, 2018 | Amgen |
| NCT05873907 | Phase 1 | Oct 19, 2015 | Amgen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 5 | 5 | 2 | 2015 |
1 organizations
Page 1 / 1